MY01 Inc., a medical technology company that uses microsensors to aid physicians in diagnosing compartment syndrome, raises US $12.5 million Series A funding round to accelerate its growth.
This financing will help the company with its mission to empower healthcare professionals and will support MY01’s goal of becoming the gold standard in the diagnosis of compartment syndrome. Also, the funding will be used to expand commercialization activities of the company in the United States.
The round was led by multiple investors including Investissement Quebec, Desjardins and Fondaction.
A Fasken team composed of Anne-Marie Naud, Anthony Sylvain, Julien Langlois and Aurélie Ménard (M&A), Jean-Philippe Mikus and Isabelle Kalar (IP), William Deneault-Rouillard (Privacy), Dara Jospé (Regulatory), Rhonda Grintuch and Florence Gauthier (Labour) and Stephanie Heinsohn-Spiropoulos (Immigration) represented investors Investissement Québec, Desjardins and Fondaction in this transaction.
Jurisdiction
- Québec
